Hexamethylmelamine and melphalan as salvage therapy in advanced ovarian carcinoma

Margaret A. Tempero, Margaret Anne Kessinger

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Ten patients with advanced ovarian carcinoma were treated with hexa‐methylmelamine and melphalan after failing first‐line combination chemotherapy. In eight patients residual disease was evident only at second‐look laparotomy. Surgical debulking was accomplished in four patients but only two patients had residual disease of less than 2 cm. Two of these four patients are alive without evidence of disease at 20 and 24 months. The remaining patients have expired (median survival 6 months). The combination of hexamethylmelamine and melphalan after surgical debulking at second‐look operation may improve the salvage of patients with advanced ovarian carcinoma.

Original languageEnglish (US)
Pages (from-to)159-161
Number of pages3
JournalJournal of Surgical Oncology
Volume21
Issue number3
DOIs
StatePublished - Jan 1 1982

Fingerprint

Altretamine
Salvage Therapy
Melphalan
Carcinoma
Combination Drug Therapy
Laparotomy
Survival

Keywords

  • hexamethylmelamine
  • melphalan
  • ovarian neoplasms

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Hexamethylmelamine and melphalan as salvage therapy in advanced ovarian carcinoma. / Tempero, Margaret A.; Kessinger, Margaret Anne.

In: Journal of Surgical Oncology, Vol. 21, No. 3, 01.01.1982, p. 159-161.

Research output: Contribution to journalArticle

Tempero, Margaret A. ; Kessinger, Margaret Anne. / Hexamethylmelamine and melphalan as salvage therapy in advanced ovarian carcinoma. In: Journal of Surgical Oncology. 1982 ; Vol. 21, No. 3. pp. 159-161.
@article{d7ecd31fb1b446b68e71636fb0fbe82c,
title = "Hexamethylmelamine and melphalan as salvage therapy in advanced ovarian carcinoma",
abstract = "Ten patients with advanced ovarian carcinoma were treated with hexa‐methylmelamine and melphalan after failing first‐line combination chemotherapy. In eight patients residual disease was evident only at second‐look laparotomy. Surgical debulking was accomplished in four patients but only two patients had residual disease of less than 2 cm. Two of these four patients are alive without evidence of disease at 20 and 24 months. The remaining patients have expired (median survival 6 months). The combination of hexamethylmelamine and melphalan after surgical debulking at second‐look operation may improve the salvage of patients with advanced ovarian carcinoma.",
keywords = "hexamethylmelamine, melphalan, ovarian neoplasms",
author = "Tempero, {Margaret A.} and Kessinger, {Margaret Anne}",
year = "1982",
month = "1",
day = "1",
doi = "10.1002/jso.2930210305",
language = "English (US)",
volume = "21",
pages = "159--161",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Hexamethylmelamine and melphalan as salvage therapy in advanced ovarian carcinoma

AU - Tempero, Margaret A.

AU - Kessinger, Margaret Anne

PY - 1982/1/1

Y1 - 1982/1/1

N2 - Ten patients with advanced ovarian carcinoma were treated with hexa‐methylmelamine and melphalan after failing first‐line combination chemotherapy. In eight patients residual disease was evident only at second‐look laparotomy. Surgical debulking was accomplished in four patients but only two patients had residual disease of less than 2 cm. Two of these four patients are alive without evidence of disease at 20 and 24 months. The remaining patients have expired (median survival 6 months). The combination of hexamethylmelamine and melphalan after surgical debulking at second‐look operation may improve the salvage of patients with advanced ovarian carcinoma.

AB - Ten patients with advanced ovarian carcinoma were treated with hexa‐methylmelamine and melphalan after failing first‐line combination chemotherapy. In eight patients residual disease was evident only at second‐look laparotomy. Surgical debulking was accomplished in four patients but only two patients had residual disease of less than 2 cm. Two of these four patients are alive without evidence of disease at 20 and 24 months. The remaining patients have expired (median survival 6 months). The combination of hexamethylmelamine and melphalan after surgical debulking at second‐look operation may improve the salvage of patients with advanced ovarian carcinoma.

KW - hexamethylmelamine

KW - melphalan

KW - ovarian neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0020423597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020423597&partnerID=8YFLogxK

U2 - 10.1002/jso.2930210305

DO - 10.1002/jso.2930210305

M3 - Article

VL - 21

SP - 159

EP - 161

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -